Search

Displaying results 6051 - 6060 of 10000 in total
  1. Drug

    Zeprumetostat

    go.drugbank.com/drugs/DB21740
    Investigational

    Zeprumetostat is a small molecule drug. The usage of the INN stem '-metostat' in the name indicates that Zeprumetostat is a histone N-methyltransferase inhibitor. … Zeprumetostat has a monoisotopic molecular weight of 548.34 Da.

  2. Drug

    Adomiparin

    go.drugbank.com/drugs/DB06005
    Investigational

  3. Drug

    Linifanib

    go.drugbank.com/drugs/DB06080
    Investigational

    Linifanib (ABT-869) is a small molecule vascular endothelial growth factor (VEGF) receptor-based kinase inhibitor that is designed to suppress tumor growth by preventing the formation of new blood vessels

    Synonyms: N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N1-(2-fluoro-5-methylphenyl) urea, UREA, N-(4-(3-AMINO-1H-INDAZOL-4-YL)PHENYL)-N'-(2-FLUORO-5-METHYLPHENYL)-
  4. Drug

    DP-VPA

    go.drugbank.com/drugs/DB05821
    Investigational

    DP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure

  5. Drug

    Darapladib

    go.drugbank.com/drugs/DB06311
    Investigational

  6. Drug

    GR270773

    go.drugbank.com/drugs/DB06427
    Investigational

    infusion between healthy adults and those with damaged livers) and NCT00089986 (completed with results, treatment of suspected or confirmed gram-negative severe sepsis in adults, comparing GR270773 with a

  7. Drug

    JSM 6427

    go.drugbank.com/drugs/DB06139
    Investigational

    JSM 6427 is the first small molecule alpha5beta1 integrin receptor antagonist of its kind to be developed. It has been biologically validated for therapeutic use in the prevention and treatment of wet AMD, the leading cause of blindness ...

  8. Drug

    AMP-201

    go.drugbank.com/drugs/DB18663
    Experimental

    AMP-201 comprises an adeno-associated virus type 8 vector (AAV8) encoding the collagen Q gene (COLQ). It is under investigation for the treatment of collagen Q congenital myasthenia.

  9. Drug

    Minzasolmin

    go.drugbank.com/drugs/DB18961
    Investigational

    Minzasolmin is under investigation in clinical trial NCT05543252 (An Extension Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's

  10. Drug

    NRP369

    go.drugbank.com/drugs/DB06384
    Experimental

    NRP369 is an oxycodone derivative under investigation for the treatment of pain (moderate to moderately severe). NRP369 was developed by New River Pharmaceuticals as a backup therapeutic to [NRP290].